User:Ewingdo/sandbox/Clinical trial template

Systolic Blood Pressure Intervention Trial
Systolic Blood Pressure Intervention Trial
Study type	Randomized controlled trial
Dates	2010–2015
Locations	102 clinical sites in the US
Funding	National Institutes of Health
Published	2015
Article	Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. (November 2015). "A Randomized Trial of Intensive versus Standard Blood-Pressure Control". The New England Journal of Medicine. 373 (22): 2103–2116. doi:10.1056/NEJMoa1511939. PMC 4689591. PMID 26551272.

The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled, clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina. The study was sponsored by the pharmaceutical company Merck and enrolled 4,444 people from 94 centres in Scandinavia.^[1]^[2]

Before the 4S study, it was not proven that lowering cholesterol could prolong life in people who had CHD.^[3] The study concluded that secondary prevention with simvastatin in a high-risk group with CHD reduced the overall mortality by 30%.

Background and objectives

Methods

Results

Conclusions

Criticism

References

^ Frishman, William H.; Cheng-Lai, Angela; Nawarskas, James (2005). "11. Lipd-lowering drugs". Current Cardiovascular Drugs. Springer Science & Business Media. p. 307. ISBN 1-57340-221-4.
^ "Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction". The American Journal of Cardiology. 71 (5): 393–400. 15 February 1993. doi:10.1016/0002-9149(93)90438-i. ISSN 0002-9149. PMID 8430625.
^ Myat, Aung; Gershlick, A. H.; Gershlick, Tony (2012). Landmark Papers in Cardiovascular Medicine. Oxford University Press. p. 31. ISBN 978-0-19-959476-4.